Andrea D. Raymond, Ph.D.

Assistant Professor

Center of Personalized Nanomedicine

Institute for NeuroImmune Pharmacology

Office: AHC1, Room 417B

E-mail: , Phone: 305-348-4648

Dr. Raymond received her doctorate in Microbiology and Immunology from Temple University School of Medicine in 2005. She completed two postdoctoral fellowships – University of Pennsylvania/Wistar, Philadelphia, PA and Morehouse School of Medicine, Atlanta, GA before joining the faculty at Herbert Wertheim College of Medicine at Florida International University. Dr. Raymond is dedicated to understanding the mechanisms of HIV pathogenesis and developing novel therapeutic strategies to fight against HIV/AIDS. Through her research Dr. Raymond has designed and implemented several studies that directly examine the effects of HIV on immune cell function. While at theWistar Institute Dr. Raymond performed translational studies where she used the bench-to-bedside concept to study macrophage responses to HIV infection in HIV-infected patients. Dr. Raymond initiated studies examining the role of macrophage-derived exosomes in HIV infection at Morehouse School of Medicine. She has published over fifteen peer-reviewed research articles. Dr. Raymond joined Herbert Wertheim College of Medicine in 2012 where she is building on her previous studies to make significant contributions to the research efforts in HIV/AIDS focusing specifically on NeuroAIDS and substance abuse, the role exosomes and HIV neuropathogenesis, and the development of novel nanotherapeutics to treat NeuroAIDS within the Department of Immunology.

Research Interests

(1)Understanding molecular mechanism(s) of HIV-1 neuropathogenesis and the role ofNef/Nef+ exosomes in HIV-associated pathogenesis in the context of substanceabuse.

(2)Developing a targeted nanomedicine approach to treatHIV-associated neuropathogenesis.

(3)Antiviral Innate Immunity in the CNS: Enhancing response to HIV and other neurotropic viruses via exosomes.

Publications(selected):

  1. RaymondAD, Diaz P, Chevelon S, Agudelo M, Yndart-Arias A, Ding H, Kaushik A, Jayant RD, Nikkhah-Moshaie R, Roy U, Pilakka-Kanthikeel S, Nair MP., Microglia-derived HIV Nef+ exosomes impairment of the blood-brain-barrier is treatable by nanomedicine-based delivery of Nef peptides. J Neurovirol. 2016 Apr;22(2):129-39; Epub 2015 Dec 2. PMID:26631079
  2. Khan MB, Lang MJ, Huang MB, Raymond A, Bond VC, Shiramizu B, Powell MD. Nefexosomes isolated from the plasma of individuals with HIV-associated dementia (HAD) can induce Aβ1-42 secretion in SH-SY5Y neural cells.J Neurovirol. 2015, PMID: 26407718.
  3. Roy U, Ding H, Pilakka-Kanthikeel S, Raymond AD, Atluri V, Yndart A, Kaftanovskaya EM, Batrakova E, Agudelo M, Nair M. Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue.Int J Nanomedicine. 2015 Sep 18;10:5819-35. PMID:26425084
  4. SudheeshPilakka-Kanthikeel, Andrea Raymond,VenkataSubba Rao Atluri, VidyaSagar,Shailendra K Saxena and Madhavan Nair. SAMHD1 facilitated HIV restriction in astrocytes is regulated by miR-155 and 181a. Journal of Neuroinflammation. 2015, PMID:25890101
  5. Ding H, Sagar V, Agudelo M, Pilakka-Kanthikeel S, Atluri VS, Raymond A, Samikkannu T, Nair MP. Enhanced blood-brain barrier transmigration using a novel Transferrin-conjugated fluorescent magneto-liposome nanoformulation. Nanotechnology 2014 Feb 7;25(5); PMID: 24406534
  6. Raymond AD, Campbell-Sims TC, Khan M, Lang M, Huang MB, Bond VC, Powell MD. HIV Type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals. AIDS Res Hum Retroviruses. 2011 Feb;27(2):167-78.PMID: 20964480

Complete List of published work in MyBibliography